Medical supply shortages flagged

Medical supply shortages remain a live risk in the U.S., with federal reports still pointing to weak links in gloves, drug ingredients and the raw chemicals used to make them. (gao.gov) A basic split drives the problem: active pharmaceutical ingredients are the core chemicals in a medicine, while key starting materials are the upstream inputs used to make those chemicals. The Administration for Strategic Preparedness and Response said on June 24, 2025 that securing domestic production of all three layers — starting materials, ingredients and finished doses — remains a federal priority. (aspr.hhs.gov) The Government Accountability Office said drug shortages were still a “serious public health problem” and that the Food and Drug Administration was tracking 102 shortages as of July 31, 2024. The office said shortages have generally lasted longer since the COVID-19 pandemic began in 2020, even as the number of newly reported shortages per year eased. (gao.gov) Federal health policy staff described the underlying market as “brittle, disruption-prone, and too slow to recover from shortages” in a 2024 report on pharmaceutical supply chains. That report tied shortages not just to factory breakdowns, but also to thin profit margins, concentrated production and weak incentives to build backup capacity. (aspe.hhs.gov) Gloves sit in the same pattern. HHS said the nitrile glove supply chain still depends on overseas manufacturing and imported raw materials, with medical-grade glove production concentrated in Southeast Asia near precursor supply networks. (aspr.hhs.gov) Washington has spent to build domestic glove lines, but those projects also show how narrow the base remains. ASPR said Health Supply US was funded to reach 360.4 million nitrile gloves a month by January 2024, and a separate award to U.S. Medical Glove Co. aimed to expand U.S. capacity and create up to 3,000 direct jobs. (aspr.hhs.gov) The same strategy is now being pushed deeper into drug chemistry. HHS said in July 2025 that a domestic manufacturing push with Phlow was meant to secure an “independent supply” of active pharmaceutical ingredients and key starting materials, not just finished medicines. (aspr.hhs.gov) FDA has also warned that weak visibility can turn a supply disruption into a care problem before hospitals have time to react. The agency said early awareness is essential, but for medical devices there are no standing mandatory shortage-reporting rules outside public health emergencies, leaving providers to manage with incomplete information. (fda.gov) The upshot is that the pandemic-era shortages never fully ended as a policy issue; they shifted into a slower fight over where the U.S. makes basic medical goods and how many backup suppliers it has. Federal agencies are still funding new capacity because a supply chain that breaks at the glove, raw-material or ingredient stage can still push prices up and leave hospitals scrambling. (aspr.hhs.gov)